Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00400686 · ClinicalTrials.gov registry record · NA
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00400686 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 31 participants.
The verdict
NCT00400686, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia in patients with multiple myeloma. PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in patients undergoing chemotherapy for multiple myeloma.
Interventions
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2003-09 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00400686
The ClinicalTrials.gov registry entry for NCT00400686 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epoetin alfa is the first listed.
NCT00400686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00400686 about?
NCT00400686 is a clinical study titled "Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma". RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia in patients with multiple myeloma. PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in patients undergoing chemotherapy for multiple myeloma.
What is the current status of trial NCT00400686?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2003-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00400686?
The interventions under investigation include: epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00400686?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.